Recent advances in the management of gastrointestinal stromal tumors

Current Oncology Reports

Volumn 5, Issue 4, 2003, Pages 288-294

  von Mehren, Margaret ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROSTALLICIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; MITOMYCIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTIGEN EXPRESSION; CLINICAL TRIAL; DRUG CLEARANCE; DRUG ERUPTION; DRUG MECHANISM; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; MESENCHYME; NAUSEA AND VOMITING; PATIENT CARE; PREDICTION; PROGNOSIS; REVIEW; TREATMENT OUTCOME; WILD TYPE; CONTROLLED CLINICAL TRIAL; FEMALE; GASTROINTESTINAL TUMOR; GENETIC PREDISPOSITION; GENETICS; MALE; MORTALITY; MUTATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL;

FEMALE; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037996348     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0068-9     Document Type: Review

References (45)

1. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
2. Fletcher CD, Berman JJ, Corless C, et al.: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33:459-465.
3. Iijima S, Maesawa C, Sato N, et al.: Gastrointestinal stromal tumour of the oesophagus: significance of immunohistochemical and genetic analyses of the c-kit gene. Eur J Gastroenterol Hepatol 2002, 14:445-448.
4. Miettinen M, Sobin LH: Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol 2001, 25:1433-1437.
5. Takahashi Y, Noguchi T, Takeno S, et al.: Gastrointestinal stromal tumor of the duodenal ampulla: report of a case. Surg Today 2001, 31:722-726.
6. Miettinen M, Furlong M, Sarlomo-Rikala M, et al.: Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001, 25:1121-1133.
7. Sakurai S, HishimaT, Takazawa Y, et al.: Gastrointestinal stromal tumors and KIT-positive mesenchymal cells in the omentum. Pathol Int 2001, 51:524-531.
8. Fukuda H, Suwa T, Kimura F, et al.: Gastrointestinal stromal tumor of the lesser omentum: report of a case. Surg Today 2001, 31:715-718.
9. Shabahang M, Livingstone AS: Cutaneous metastases from a gastrointestinal stromal tumor of the stomach: review of literature. Dig Surg 2002, 19:64-65.
10. Nishida T, Hirota S, Taniguchi M, et al.: Familial gastrointestinal stromal tumors with germline mutation of the KIT gene. Nat Genet 1998, 19:323-324.
11. Maeyama H, Hidaka E, Ota H, et al.: Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001, 120:210-215.
12. Carney JA: Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999, 74:543-552.
13. Li P, Wei J, West AB, Perle M, et al.: Epithelioid gastrointestinal stromal tumor of the stomach with liver metastases in a 12-year-old girl: aspiration cytology and molecular study. Pediatr Dev Pathol 2002, 5:386-384.
14. Lee JR, Joshi V, Griffin JW Jr, et al.: Gastrointestinal autonomic nerve tumor: immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001, 25:979-987.
15. Miettinen M, El-Rifai W, L HLS, Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002, 33:478-483.
16. Panizo-Santos A, Sola I, Vega F, et al.: Predicting metastatic risk of gastrointestinal stromal tumors: role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol 2000, 8:133-144.
17. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999, 154:53-60.
18. Rubin B, Singer S, Tsao C, et al.: Activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61:8118-8121.
19. Coreless CL, McGreevey L, Haley A, et al.: KIT Mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002, 160:1567-1572.
20. Heinrich M, Blanke C, Druker B, Corless C: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002, 20:1692-1703.
21. Heinrich M, Rubin B, Longley B, Fletcher J: Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002, 33:484-495.
22. Andersson J, Sjogren H, Meis-Kindblom JM, et al.: The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002, 160:15-22.
23. Heinrich MC, Coreless CL, Duensing A, et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-10.
24. Hasegawa T, Matsumo Y, Hirohashi S: Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002, 33:669-676.
25. Singer S, Rubin B, Lux M, et al.: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002, 20:3898-3905.
26. Gunawan B, Bergmann F, Hoer J, et al.: Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 2002, 33:316-321.
27. El-Rifai W, Sarlomo-Rikala M, Andersson LC, et al.: DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000, 60:3899-903.
28. Edmonson JH, Marks RS, Buckner JC, Mahoney MR: Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002, 20:605-612.
29. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002, 33:466-477.
30. van Oosterom A, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
31. Demetri G, vonMehren M, Blanke C, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
32. Buchdunger E, Zimmermann J, Mett H, et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100-104.
33. Buchdunger E, Cioffi CL, Law N, et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139-145.
34. Blanke C, vonMehren M, Joensu H, et al.: Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (pts) with unresectable or metastatic gastrointestinal Stromal Tumors (GISTS) expressing c-kit (CD117) [abstract]. Proc ASCO. 2001, 20:1.
35. Benjamin R, Rankin C, Fletcher C, et al.: Phase III dose-randomized study of imatinib mesylate (IM) for GIST: Intergroup S0033 early results [abstract]. Proc ASCO 2003.
36. Verweij J, Casali P, Zalcgerg J, et al.: Early efficacy comparison of two doses of imatinib for the treatment of advanced Gastrointestinal Stromal Tumors (GIST): interim results of a randomized phase III trial form the EORTC-STBSG, ISG and AGITG [abstract]: Proc ASCO 2003.
37. Van Glabbeke M, Verweij J, Casali P, et al.: Prognostic factors of toxicity and efficacy in patients with Gastro-Intestinal Stromal Tumors (GIST) treated with imatinib: a study of the EORTC-STBSG, ISG and AGITG [abstract]. Proc ASCO 2003.
38. Judson I, Donato Di Paloa E, Verweij J, et al.: Population pharmacokinetic (PK) analysis and PK-pharmacodynamic (PD) correlations in phase I/II trial of imatinib in gastrointestinal stromal tumours (GIST) conducted by the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group [abstract]. Proc ASCO 2003.
39. Heinrich M, Corless CL, Demetri G, et al.: Mechanisms of resistance to imatinib mesylate (IM) in advanced gastointestinal stromal tumors (GISTs) [abstract] Proc ASCO 2003.
40. von Mehren M, Blanke C, Joensuu H, et al.: High incidence of durable responses induced by Imatinib mesylate (Gleevec™) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs) [abstract]. Proc ASCO 2002, 21:1608.
41. van Oosterom A, Judson I, Verweij J, et al.: Update of imatinib (STI571, Glivec) phase I study in gastrointestinal stromal tumors (GISTs) [abstract]. Proc ASCO 2002, 21:327.
42. Druker BJ: Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003, 40:50-58.
43. Fletcher J, Corless C, Dimitrijevic S, et al.: Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST) [abstract] Proc ASCO 2003.
44. Frolov A, Chawan S, Pan ZZ, et al.: Identification of response markers and the moclecular mechanism of action [abstract]. Proc AACR 2003.
45. Demetri G, George S, Heinrich MC, et al.: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate [abstract]. Proc ASCO 2003.